Wednesday, June 10, 2026
🇺🇸 FDA

pharma · Relapsing-Remitting Multiple Sclerosis · Spinal Muscular Atrophy

Biogen

Biogen trial registry — 31 ClinicalTrials.gov studies with program phase, status, and indication context.

Website Investor relations
225 Binney Street, Cambridge, MA 02142, US HQ
7,534 Employees
NMPA registrant Type
Company details
Status
Public
HQ
225 Binney Street, Cambridge, MA 02142, US
Employees
7,534
Programs
31
Drugs
45
Patents
25
Official website ↗ All projects Drug pipeline Patents News & analysis

Recent coverage

View all news & analysis →
Intelligence · Clinical Trials

Biogen clinical trials

Registry index of 31 ClinicalTrials.gov studies linked to Biogen programs — each row shows trial ID, program name, phase, status, and indication.

Biogen trial registry — 31 ClinicalTrials.gov studies with program phase, status, and indication context.

Recent trial activity

8 updates

Latest clinical program signals indexed for Biogen.

  1. EnEPC-CLI-01 — Phase 2

    Clinical update

  2. 299AR301 — Phase 3

    Clinical update

  3. 299AR201 — Phase 2

    Clinical update

  4. 283PD201 — Phase 2

    Clinical update

  5. 277HV101 — Phase 1

    Clinical update

  6. 230LE304 — Phase 3

    Clinical update

  7. 230LE303 — Phase 3

    Clinical update

  8. 230LE301 — Phase 3

    Clinical update

Trial registry

31 studies
  16. 2024-516665-36-00

    EnEPC-CLI-01

    Phase 2 active small_molecule

    Peripherial arterial disease (PAD) & Chronic-Limb Threatening Ischemia (CLTI) patients who have not responded to standard pharmacological treatment or control of risk factors, and/or had a revascularisation with continued presence of smaller vessel (microvasculature) disease, and do not have the option of a revascularization treatment.

    CTIS ↗

Drug approvals, clinical trials, M&A, event intelligence, and company updates — weekly.

Customize topics & region
Topics
Region

No spam. Unsubscribe anytime. See our privacy policy.